\square

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287					
Estimated average burden						
hours per response:	0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person [*] <u>McKinstry Nancy</u>			2. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES</u> [ABT]		ationship of Reporting Person(s) to Issuer k all applicable) Director 10% Owner		
(Last) 100 ABBOTT PA	(First) RK ROAD	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 04/23/2021		Officer (give title below)	Other (specify below)	
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	idual or Joint/Group Filing	(Check Applicable	
(Street)	()						
ABBOTT PARK	кп	60064			X Form filed by One Reporting Person Form filed by More than One Reportin Person		
(City)	(State)	(Zip)					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common shares without par value	04/23/2021		A		1,499(1)	Α	\$ <mark>0</mark>	27,139	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date if any 6. Date Exercisable and Expiration Date (Month/Day/Year) 1. Title of Derivative 5. Number 7. Title and Amount of 8. Price of Derivative 9. Number of derivative 10. Ownership 11. Nature of Indirect 2. Conversion 4. Transaction Code (Instr. 8) Derivative Securities Security (Instr. 5) Form: Security or Exercise Securities Beneficial Direct (D) Price of Derivative Underlying Derivative Security (Instr. 3) (Month/Dav/Year) Securities Beneficially Ownership Acquired (A) or Disposed of (D) (Instr. 3, 4 Owned or Indirect (I) (Instr. 4) (Instr. 4) Security (Instr. 3 and 4) Following Reported Transaction(s) (Instr. 4) and 5) Amount or Number Expiration Date of Shares v (A) (D) Exercisable Date Title Code Option Commor (right to buy)⁽²⁾ \$123.38 04/23/2021 A 7,035 04/23/2021 04/22/2031 7,035 \$<mark>0</mark> 7,035 D Shares

Explanation of Responses:

1. These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

2. Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

/s/ Nancy McKinstry by Jessica	04/22/2021
H. Paik, Attorney-in-Fact	04/23/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.